Leaflet ORFIRIL LONG 1000mg prolonged-release mini-tablets
Indicated for: epilepsy; bipolar disorder
Substance: valproic acid + salts (antiepileptics)
ATC: N03AG01 (Nervous system | Antiepileptics | Fatty acid derivatives)
Valproic acid and its salts (e.g., sodium valproate) are used to treat epilepsy, bipolar disorder, and prevent migraines. They stabilize brain electrical activity, preventing seizures and episodes of mania or depression.
Valproic acid increases GABA (gamma-aminobutyric acid) levels, an inhibitory neurotransmitter, reducing neuronal excitability. It is indicated for generalized and focal epilepsy, bipolar disorder, and migraine prevention.
Side effects may include nausea, drowsiness, weight gain, or tremor. Rarely, it can affect the liver or pancreas. It is contraindicated during pregnancy due to the risk of congenital malformations. Treatment must be monitored by a doctor.
General data about ORFIRIL LONG 1000mg
- Substance: valproic acid + salts
- Date of last drug list: 01-05-2026
- Commercial code: W08325001
- Concentration: 1000mg
- Pharmaceutical form: prolonged-release mini-tablets
- Quantity: 50
- Product type: generic
- Price: 113.35 RON
- Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.
Pharmaceutical forms available for valproic acid + salts
- capsules with prolonged-release mini-tablets
- prolonged release capsules
- gastro-resistant soft capsules
- prolonged-release tablets
- film-coated tablets
- modified-release film-coated tablets
- gastro-resistant film-coated tablets
- gastro-resistant tablets
- prolonged-release granules
- lyophilizate+solvent for solution
- syrup
Concentrations available for valproic acid + salts
- 1000mg
- 100mg
- 150mg
- 200mg
- 200mg/5ml
- 250mg
- 300mg
- 300mg/5ml
- 400mg/4ml
- 500mg
- 50mg/ml
- 57.64mg/ml
- 600mg
- 750mg